Christina Wu MD


Christina Wu MD
Asst Professor - ClinicalCollege of Medicinewu.1439@osu.edu
Starling Loving Hall 320 W 10th Avenue Columbus Ohio 43210
Phone:Fax: (614) 293-7520
  • Molecular Biology and Cancer Genetics

General Research Interest

Dr. Wu has focused her research on the molecular characterization of colorectal cancer to discover new biomarkers and therapeutic agents. She is specifically interested in discovering pathways that drive KRAS mutant colorectal cancers, and exploring the molecular characteristics of microsatellite instable tumors and their effects on sensitivity to therapy and survival outcomes

Research Description

Dr. Wu’s research involves both translational and clinical studies. She is the co-principal investigator of a phase I clinical trial of trametinib, a MEK inhibitor, in combination with neoadjuvant chemoradiation in rectal cancers that have either KRAS, NRAS, or BRAF mutation, and the principal investigator of a phase II clinical trial of panitumumab and chemotherapy in patients with advanced KRAS wild-type colorectal cancer after prior therapy with bevacizumab. Pre-clinical research projects include analyzing colorectal cancer tumors that carry microsatellite instable characteristics and correlating those features with survival and treatment efficacy. Another research project she is currently involved in is titled ”Therapeutic Targeting KRAS Mutation-Driven Tumor Progression and Liver Metastasis in Colorectal Cancer.”

Current Publications

  • Bekaii-Saab T, Wu CSeeing the forest through the trees: A systematic review of the safety and efficacy of combination chemotherapies used in the treatment of metastatic colorectal cancer.Crit Rev Oncol Hematol 91 9-34 7/1/2014
  • Haraldsdottir S, Hampel H, Wei L, Wu C, Frankel W, Bekaii-Saab T, de la Chapelle A, Goldberg RMProstate cancer incidence in males with Lynch syndrome.Genet Med 16 553-7 7/1/2014
  • Jiang Y, Wang J, Rozewski DM, Kolli S, Wu CH, Chen CS, Yang X, Hofmeister CC, Byrd JC, Johnson AJ, Phelps MASensitive liquid chromatography/mass spectrometry methods for quantification of pomalidomide in mouse plasma and brain tissue.J Pharm Biomed Anal 88 262-8 1/1/2014
  • Wu C, Fernandez SA, Criswell T, Chidiac TA, Guttridge D, Villalona-Calero M, Bekaii-Saab TSDisrupting cytokine signaling in pancreatic cancer: a phase I/II study of etanercept in combination with gemcitabine in patients with advanced disease.Pancreas 42 813-8 7/1/2013
  • Haraldsdottir S, Wu C, Bloomston M, Goldberg RMWhat is the optimal neo-adjuvant treatment for liver metastasis?Ther Adv Med Oncol 5 221-34 7/1/2013
  • Olson EM, Abdel-Rasoul M, Maly J, Wu CS, Lin NU, Shapiro CLIncidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab.Ann Oncol 24 1526-33 6/1/2013
  • Wu C, Goldberg RMColorectal cancer in 2012: Revisiting landmark trials and identifying new therapies.Nat Rev Clin Oncol 10 71-2 2/1/2013
  • Wu C, Goldberg RMManaging choices for older patients with colon cancer: adjuvant therapy.Am Soc Clin Oncol Educ Book 1/1/2013

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu